Notal Vision announced a collaboration with the American Academy of Ophthalmology (AAO) IRIS (Intelligent Research in Sight) Registry, a partnership designed to better understand real-world visual acuity in patients with age-related macular degeneration (AMD).
The IRIS Registry is the first and largest comprehensive source of eye disease data nationwide, holding clinical information from over 16,000 participating physicians and over 140 million patient visits through July 1, 2017. Landmark clinical studies of anti-VEGF therapy for AMD have demonstrated that the best predictor of visual outcomes is baseline VA. Absolute vision remains significantly better over time in patients that have a better VA at diagnosis and treatment initiation. In an effort to better understand this predictor and characterize VA, Notal will evaluate data from the IRIS Registry on VA at the time of AMD diagnosis across all eyes, as well as the first eye and second eye to convert. Additional analyses will examine relationships between VA at diagnosis and longer term treatment outcomes and number of injections required.
"The IRIS Registry is the most robust ophthalmic resource for real-world clinical data, treatment patterns, and outcomes in the U.S.," Susan Orr, OD, Chief Medical Officer & Vice President of Medical Affairs, said in the news release. "We are thrilled to collaborate with the AAO to gain real-world evidence surrounding VA at time of diagnosis, and explore the potential benefit over time of early wet AMD detection."
The IRIS Registry will be the subject of a symposium during the American Academy of Ophthalmology on Saturday, November 11 from 12:15 to 1:15 pm titled, "The Value of the IRIS Registry: What Can We Learn From 100 Million Patient Records?" The value of IRIS Registry lies not only within its ability to support Academy members in meeting the increased demands of quality reporting, but also in driving true improvements in quality and patient outcomes, and enhancing clinical knowledge and advance scientific discoveries.